Medication Administration Record

Total Page:16

File Type:pdf, Size:1020Kb

Medication Administration Record Department of Health and Human Services MAINE Division of Licensing and Certification CiSiP September 2005 The Maine Department of Health and Human Services does not discriminate against people on the basis of disability, race, color, creed, gender, age or national origin in admission to, access to, or operations of its programs, services or activities, or its hiring or employment practices. This information is available in alternate format upon request. CRMA RECERTIFICATION CURRICULUM SEPTEMBER 2005 Page 2 of 177 TABLE OF CONTENTS Section 1..................................................................................................................9 CRMA Role............................................................................................................9 • Certification Limitations......................................................................................................................... 9 • Job Description..................................................................................................................................... 10 • Other Staff Roles................................................................................................................................... 10 • Key Responsibilities............................................................................................................................. 10 • Characteristics....................................................................................................................................... 10 Section 2................................................................................................................11 INSTRUCTIONS FOR DOCUMENTATION EXERCISE ...........................11 PHYSICIAN’S ORDERS ...................................................................................12 RESIDENT CARE NOTES................................................................................13 Medication Administration Record......................................................................14 Medication Disposal Form................................................................................................................................ 16 Medication Error Form............................................................................................................................... 17 Medication Sign Out Record Form ......................................................................................................... 18 Missed or Late Medications ...................................................................................................................... 19 Over The Counter Medication Form....................................................................................................... 20 Physician’s Order......................................................................................................................................... 21 CRMA – RECERT Medication Administration Skills Checklist.................................................................... 22 Section 3................................................................................................................25 MEDICAL ABBREVIATIONS.........................................................................25 Section 4................................................................................................................28 MEDICATION MEASUREMENTS.................................................................28 Systems of Measurement..................................................................................................................... 28 • Metric Terms......................................................................................................................................... 28 • Apothecary System Description ........................................................................................................... 29 • Household System Description............................................................................................................. 29 • Metric System ....................................................................................................................................... 29 • Weight................................................................................................................................................... 29 CRMA RECERTIFICATION CURRICULUM SEPTEMBER 2005 Page 3 of 177 • Volume.................................................................................................................................................. 30 • Length ................................................................................................................................................... 30 Apothecary System................................................................................................................................. 30 • Weight -- (Dry) ..................................................................................................................................... 30 • Volume -- (Wet).................................................................................................................................... 30 Household System .................................................................................................................................. 31 Equivalent Dry Measurement Units............................................................................................... 31 Equivalent Liquid Measurement Units......................................................................................... 32 Section 5................................................................................................................33 Review of Drug Classifications...........................................................................33 Medication Classification Terms and Definitions ............................................33 Section 6................................................................................................................36 Medication Orders ..............................................................................................36 • Obtaining Medication Orders ............................................................................................................... 36 • Prescription ........................................................................................................................................... 36 • Duly Authorized Licensed Practitioner Order ...................................................................................... 36 Psychotropic PRN’s..................................................................................................................................... 37 Calling In Orders.......................................................................................................................................... 37 Appointment for Service/Order Sheet .................................................................................................... 37 Telephone Orders......................................................................................................................................... 38 When Must Orders be Written or Re-Written?...............................................38 During the Admission Process.................................................................................................................. 38 Psychotropic Orders .................................................................................................................................... 38 Medical Orders ............................................................................................................................................. 39 Upon Discharge from a Hospitalization................................................................................................. 39 New Orders.................................................................................................................................................... 39 Changed Orders............................................................................................................................................ 40 Discontinued or Stop Orders..................................................................................................................... 41 Section 7................................................................................................................42 Medication Ordering........................................................................................................................ 42 SECTION 8..........................................................................................................43 CRMA RECERTIFICATION CURRICULUM SEPTEMBER 2005 Page 4 of 177 Documentation.....................................................................................................43 • Initials ................................................................................................................................................... 43 • Unusual Circumstances......................................................................................................................... 43 • Refusal .................................................................................................................................................. 43 Medication Administration Record (MAR)......................................................44 General Information ...................................................................................................................................
Recommended publications
  • Spider Bites
    Infectious Disease Epidemiology Section Office of Public Health, Louisiana Dept of Health & Hospitals 800-256-2748 (24 hr number) www.infectiousdisease.dhh.louisiana.gov SPIDER BITES Revised 6/13/2007 Epidemiology There are over 3,000 species of spiders native to the United States. Due to fragility or inadequate length of fangs, only a limited number of species are capable of inflicting noticeable wounds on human beings, although several small species of spiders are able to bite humans, but with little or no demonstrable effect. The final determination of etiology of 80% of suspected spider bites in the U.S. is, in fact, an alternate diagnosis. Therefore the perceived risk of spider bites far exceeds actual risk. Tick bites, chemical burns, lesions from poison ivy or oak, cutaneous anthrax, diabetic ulcer, erythema migrans from Lyme disease, erythema from Rocky Mountain Spotted Fever, sporotrichosis, Staphylococcus infections, Stephens Johnson syndrome, syphilitic chancre, thromboembolic effects of Leishmaniasis, toxic epidermal necrolyis, shingles, early chicken pox lesions, bites from other arthropods and idiopathic dermal necrosis have all been misdiagnosed as spider bites. Almost all bites from spiders are inflicted by the spider in self defense, when a human inadvertently upsets or invades the spider’s space. Of spiders in the United States capable of biting, only a few are considered dangerous to human beings. Bites from the following species of spiders can result in serious sequelae: Louisiana Office of Public Health – Infectious Disease Epidemiology Section Page 1 of 14 The Brown Recluse: Loxosceles reclusa Photo Courtesy of the Texas Department of State Health Services The most common species associated with medically important spider bites: • Physical characteristics o Length: Approximately 1 inch o Appearance: A violin shaped mark can be visualized on the dorsum (top).
    [Show full text]
  • FF #93 THC Cancer AIDS.3Rd Ed
    ! FAST FACTS AND CONCEPTS #93 CANNABINOIDS IN THE TREATMENT OF SYMPTOMS IN CANCER AND AIDS L Scott Wilner MD and Robert M Arnold MD Introduction The healing properties of cannabis have been asserted for centuries. Popular claims notwithstanding, there are no data to support the use of marijuana in the treatment of asthma, anxiety, depression, epilepsy, glaucoma, alcohol withdrawal, or infection; and limited data to support using cannabinoids as analgesics. Recent scientific studies of cannabinoids for symptom management have focused on nausea/vomiting and appetite stimulation. Terminology Cannabis sativa is the Indian hemp plant. Marijuana is a psychoactive substance derived from the plant. Cannabinoids are the biologically active compounds in the plant. THC is delta )-9 tetrahydrocannabinol, the major cannabinoid. Dronabinol is synthetic THC and the main ingredient in the Schedule 3 drug Marinol. Nabilone is an engineered THC analog that forms the basis of the Schedule 2 drug Cesamet. Pharmacology Cannabinoids act on cannabinoid receptors: the CB1 receptor in the CNS and on the CB2 receptor localized primarily to immune cells. Dronabinol and nabilone are well absorbed orally, but first pass metabolism and protein binding limit bioavailability. Dronabinol has a faster onset of action (~30 minutes), while nabilone has a longer duration of action (typically 8 – 12 hours, but potentially as long as 24 hours in some patients). Alternative delivery systems – including inhalers, suppositories, and transdermal patches – are being evaluated. Anti-emetic Use Dronabinol and nabilone are FDA approved for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetics.
    [Show full text]
  • Pharmacologic Interventions for Fatigue in Cancer and Transplantation: a Meta-Analysis
    DRUG INTERVENTIONS FOR FATIGUE, Tomlinson et al. REVIEW ARTICLE Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis † † ‡ D. Tomlinson RN MN,* P.D. Robinson MD MSc, S. Oberoi MD, D. Cataudella PsyD CPsych, § || # N. Culos-Reed PhD, H. Davis,* N. Duong,* F. Gibson RN PhD, M. Götte PhD, P. Hinds RN PhD,** †† †† † ‡‡ §§ S.L. Nijhof MD PhD, P. van der Torre, S. Cabral, L.L. Dupuis MScPhm PhD,* and L. Sung MD PhD* ABSTRACT Background Our objective was to determine whether, compared with control interventions, pharmacologic interventions reduce the severity of fatigue in patients with cancer or recipients of hematopoietic stem-cell transplantation (hsct). Methods For a systematic review, we searched medline, embase, the Cochrane Central Register of Controlled Trials, cinahl, and Psychinfo for randomized trials of systemic pharmacologic interventions for the management of fatigue in patients with cancer or recipients of hsct. Two authors independently identified studies and abstracted data. Methodologic quality was assessed using the Cochrane Risk of Bias tool. The primary outcome was fatigue severity measured using various fatigue scales. Data were synthesized using random-effects models. Results In the 117 included trials (19,819 patients), the pharmacologic agents used were erythropoietins (n = 31), stimulants (n = 19), l-carnitine (n = 6), corticosteroids (n = 5), antidepressants (n = 5), appetite stimulants (n = 3), and other agents (n = 48). Fatigue was significantly reduced with erythropoietin [standardized mean difference (smd): –0.52; 95% confidence interval (ci): –0.89 to –0.14] and with methylphenidate (smd: –0.36; 95% ci: –0.56 to –0.15); modafinil (or armodafinil) and corticosteroids were not effective.
    [Show full text]
  • ALLERGIC REACTIONS/ANAPHYLAXIS Connie J
    Northwest Community EMS System Paramedic Education Program ALLERGIC REACTIONS/ANAPHYLAXIS Connie J. Mattera, M.S., R.N., EMT-P Reading assignments Text-Vol.1 pp. 235, 1272-1276 SOP: Allergic Reactions/ Anaphylactic Shock Assumed knowledge: Drugs: Epinephrine 1:1,000, 1:10,000; albuterol, ipratropium, dopamine, glucagon KNOWLEDGE OBJECTIVES Upon reading the assigned text assignments and completion of the class and homework questions, each participant will independently do the following with at least an 80% degree of accuracy and no critical errors: 1. Define allergic reaction. 2. Describe the incidence, morbidity and mortality of allergic reactions and anaphylaxis. 3. Identify risk factors that predispose a patient to anaphylaxis. 4. Explain the physiology of the immune system following exposure to an allergen including activation of histamine receptors and the formation of antibodies. 5. Discuss the pathophysiology of allergic reactions and anaphylaxis. 6. Describe the common modes by which allergens enter the body. 7. Compare and contrast natural and acquired and active vs. passive immunity. 8. Identify antigens most frequently associated with anaphylaxis. 9. Differentiate the clinical presentation and severity of risk for a mild, moderate and severe allergic reaction with an emphasis on recognizing an anaphylactic reaction. 10. Integrate the pathophysiologic principles of anaphylaxis with treatment priorities. 11. Sequence care per SOP for patients with mild, moderate and severe allergic reactions. CJM: S14 NWC EMSS Paramedic Education Program ALLERGIC REACTIONS/ANAPHYLAXIS Connie J. Mattera, M.S., R.N., EMT-P I. Immune system A. Principal body system involved in allergic reactions. Others include the cutaneous, cardiovascular, respiratory, nervous, and gastrointestinal systems.
    [Show full text]
  • Megestrol Acetate: Drug Information
    Official reprint from UpToDate® www.uptodate.com ©2017 UpToDate® Megestrol acetate: Drug information Copyright 1978-2017 Lexicomp, Inc. All rights reserved. (For additional information see "Megestrol acetate: Patient drug information" and see "Megestrol acetate: Pediatric drug information") For abbreviations and symbols that may be used in Lexicomp (show table) Brand Names: US Megace ES; Megace Oral Brand Names: Canada Megace OS; Megestrol Pharmacologic Category Antineoplastic Agent, Hormone; Appetite Stimulant; Progestin Dosing: Adult Note: Megace ES suspension is not equivalent to other formulations on a mg-per-mg basis. Anorexia or cachexia associated with AIDS: Oral: Suspension: U.S. labeling: Initial: 625 mg daily (of the 125 mg/mL suspension) or 800 mg daily (of the 40 mg/mL suspension); daily doses of 400 mg to 800 mg have been found to be effective Canadian labeling: Usual dose: 400 to 800 mg once daily for at least 2 months Breast cancer, advanced: Oral: Tablet: U.S. labeling: 160 mg per day in divided doses of 40 mg 4 times daily for at least 2 months Canadian labeling: 160 mg or 125 mg/m2 daily (40 mg 4 times daily or 160 mg once daily) for at least 2 months Endometrial cancer, advanced: Oral: Tablet: U.S. labeling: 40 to 320 mg daily in divided doses for at least 2 months Canadian labeling: 80 to 320 mg or 62.5 to 250 mg/m2 daily in divided doses (40 to 80 mg 1 to 4 times daily or 160 to 320mg daily) for at least 2 months Cancer-related cachexia: Canadian labeling: Oral: Tablet: 400 to 800 mg once daily for at least 2 months Cancer-related cachexia (off-label use/dosing in U.S.): Oral: Doses ranging from 160 to 800 mg per day were effective in achieving weight gain, higher doses (>160 mg) were associated with more weight gain (Beller, 1997; Loprinzi, 1990; Loprinzi, 1993; Vadell, 1998); based on a meta-analysis, an optimal dose has not been determined (Ruiz Garcia, 2013) Dosing: Geriatric Use with caution; refer to adult dosing.
    [Show full text]
  • Arthropod Envenomations: Immunologic and Toxicologic Considerations Cyrus Rangan, MD, FAAP, ACMT
    Emergency Department Evaluation and Treatment for Children With Arthropod Envenomations: Immunologic and Toxicologic Considerations Cyrus Rangan, MD, FAAP, ACMT Arthropod envenomations are a significant cause of environmental injury in children. Bees, wasps, and spiders inflict injury via specialized venoms with a broad range of components, mechanisms, and potential treatments. Immunologic and toxicologic considerations in the evaluation and management of arthropod envenomations are important for the under- standing of the progression of envenomations, prompt diagnosis of severe conditions including anaphylaxis, and the use of antivenom in selected cases. Clin Ped Emerg Med 8:104-109 ª 2007 Published by Elsevier Inc. KEYWORDS envenomation, arthropod, arachnida, hymenoptera rthropod bites and stings accounted for more than ever, clinical symptoms of envenomation and treatment A75000 reports to poison control centers in the are similar. Bees are attracted to carbon dioxide (hence, United States in 2005 [1]. The phylum Arthropoda the predilection for bees to fly around the facial area), includes 2 clinically important classes: Insecta (order: bright colors (ie, clothing), and sweet odors (ie, Hymenoptera—bees, wasps, yellow jackets, and ants), perfumes, fragrances). Children commonly believe that and Arachnida (ticks, scorpions, and spiders). Virtually bees are aggressive insects, but they are mostly docile all arthropods possess some form of venom for immobi- creatures; indeed, the sometimes fearful behavior of lization and digestion of prey, yet only a select few species children around a nearby bee may increase the risk of a have developed venom delivery mechanisms capable of sting. Mass envenomations may occur when a hive is poisoning humans [2]. Pathophysiologic mechanisms of physically disturbed by children throwing rocks or other venom vary considerably among arthropods, and clinical objects at the hive [3].
    [Show full text]
  • Instruction Sheet: Bee Sting, Local Reaction
    University of North Carolina Wilmington Abrons Student Health Center INSTRUCTION SHEET: BEE STING, LOCAL REACTION The Student Health Provider has diagnosed a mild allergic reaction to a bee/wasp sting. Fortunately, most bee stings are not serious and cause only temporary swelling, redness, and pain at the sting site. Rarely, a whole-body allergic reaction occurs; shock can result. The stinger, if still in the wound, should be removed; if the stinger is left in place, bee toxin continues to enter the body, increasing the reaction. A stinger should be removed with a piece of paper or credit card, using a sideways scraping motion. A pair of tweezers can also be used to remove the stinger, but try not to squeeze the stinger, or more toxin can be pushed inside the wound. Realize that swelling may increase at first, even with treatment. Measures can be taken, however, to minimize the reaction to bee stings. MEASURES YOU SHOULD TAKE TO HELP TREAT YOUR BEE STING: 1. Rest and elevate the affected body part. Rest and elevation help reduce swelling and pain. 2. Apply cold packs to the area off-and-on for the first 24 hours after injury. Cold helps ease discomfort, and minimizes additional swelling. Do not apply ice directly to the area, causing discomfort. Rather, aim for coolness, yet comfort, applying a layer or two of cloth between the cold pack and affected area. 3. Take over-the-counter antihistamines: In the morning, take a non-sedating antihistamine such as loratadine, 10 mg daily. At night, take diphenhydramine (Benadryl), 25 mg, 1 or 2 every 6 hours for itching and swelling.
    [Show full text]
  • Prioritization of Health Services
    PRIORITIZATION OF HEALTH SERVICES A Report to the Governor and the 74th Oregon Legislative Assembly Oregon Health Services Commission Office for Oregon Health Policy and Research Department of Administrative Services 2007 TABLE OF CONTENTS List of Figures . iii Health Services Commission and Staff . .v Acknowledgments . .vii Executive Summary . ix CHAPTER ONE: A HISTORY OF HEALTH SERVICES PRIORITIZATION UNDER THE OREGON HEALTH PLAN Enabling Legislatiion . 3 Early Prioritization Efforts . 3 Gaining Waiver Approval . 5 Impact . 6 CHAPTER TWO: PRIORITIZATION OF HEALTH SERVICES FOR 2008-09 Charge to the Health Services Commission . .. 25 Biennial Review of the Prioritized List . 26 A New Prioritization Methodology . 26 Public Input . 36 Next Steps . 36 Interim Modifications to the Prioritized List . 37 Technical Changes . 38 Advancements in Medical Technology . .42 CHAPTER THREE: CLARIFICATIONS TO THE PRIORITIZED LIST OF HEALTH SERVICES Practice Guidelines . 47 Age-Related Macular Degeneration (AMD) . 47 Chronic Anal Fissure . 48 Comfort Care . 48 Complicated Hernias . 49 Diagnostic Services Not Appearing on the Prioritized List . 49 Non-Prenatal Genetic Testing . 49 Tuberculosis Blood Test . 51 Early Childhood Mental Health . 52 Adjustment Reactions In Early Childhood . 52 Attention Deficit and Hyperactivity Disorders in Early Childhood . 53 Disruptive Behavior Disorders In Early Childhood . 54 Mental Health Problems In Early Childhood Related To Neglect Or Abuse . 54 Mood Disorders in Early Childhood . 55 Erythropoietin . 55 Mastocytosis . 56 Obesity . 56 Bariatric Surgery . 56 Non-Surgical Management of Obesity . 58 PET Scans . 58 Prenatal Screening for Down Syndrome . 59 Prophylactic Breast Removal . 59 Psoriasis . 59 Reabilitative Therapies . 60 i TABLE OF CONTENTS (Cont’d) CHAPTER THREE: CLARIFICATIONS TO THE PRIORITIZED LIST OF HEALTH SERVICES (CONT’D) Practice Guidelines (Cont’d) Sinus Surgery .
    [Show full text]
  • Generic Name Brand Name
    Florida AIDS Drug Assistance Program (ADAP) Formulary MAY 2021 *Indicates controlled substance. Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability. Brand Name (listed for Generic Name Therapeutic Classification Pharmacologic Classification Antiretroviral drugs only) abacavir (ABC) Ziagen Antiretroviral Nucleoside reverse transcriptase inhibitor (NRTI) abacavir/lamivudine (ABC/3TC) Epzicom Antiretroviral NRTI combo abacavir/lamivudine/zidovudine (ABC/3TC/AZT) Trizivir Antiretroviral NRTI combo atazanavir (ATV) Reyataz Antiretroviral Protease inhibitor (PI) atazanavir/cobicistat (ATV/COBI) Evotaz Antiretroviral PI/PK Enhancer bictegravir/emtricitabine/tenofovir alafenamide Biktarvy Antiretroviral INSTI/NRTI combo (BIC/TAF/FTC) cabotegravir Vocabria Antiretroviral INSTI Non-nucleoside reverse transcriptase inhibitor (NNRTI) cabotegravir/rilpivirine (CBV/RPV) Cabenuva Antiretroviral and INSTI cobicistat (COBI) Tybost Antiretroviral Pharmacokinetic enhancer darunavir (DRV) Prezista Antiretroviral Protease inhibitor (PI) darunavir/cobicistat (DRV/COBI) Prezcobix Antiretroviral PI/PK Enhancer darunavir/cobicistat/emtricitabine/tenofovir Symtuza Antiretroviral PI/NRTI combo alafenamide (DRV/COBI/FTC/TAF) dolutegravir (DTG) Tivicay Antiretroviral Integrase strand transfer inhibitor (INSTI) dolutegravir / lamivudine (DTG/3TC) Dovato Antiretroviral INSTI/NRTI combo dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) Triumeq Antiretroviral INSTI/NRTI combo dolutegravir/rilpivirine (DTG/RPV) Juluca
    [Show full text]
  • Cyproheptadine for Central Hypertension?
    OPEN ACCESS Research article Cyproheptadine for central hypertension? Guido Filler1,2,*, Lara Hart1, April Chan3, Elizabeth Cairney4, Asuri N Prasad5 1Department of Paediatrics, Division of Paediatric Nephrology, Schulich School ABSTRACT of Medicine & Dentistry, London, ON, Background: Approximately one-fifth of paediatric intracranial tumors result in hypertension. Canada N6A 5W9 2Department of Pathology and The condition is difficult to treat in this population, particularly if it is refractory, since there is little Laboratory Medicine, Schulich School of guidance on patient management beyond first-line therapy with IV labetalol. Medicine & Dentistry, University of Western Ontario, London, Ontario, Methods: A 20-month-old patient was hospitalized with cerebral herniation-induced loss of Canada N5A 5A5 consciousness and a posterior fossa mass was found. Although several first-line treatments including 3 School of Pharmacy, University of IV labetalol, furosemide, amlodipine, clonidine, and atenolol were administered, the patient’s Western Ontario, London, ON, Canada 5A 5A5 hypertension persisted. With few options left, positive findings from previously published case reports 4Department of Paediatrics, Division of led the team to administer cyproheptadine. Hematology/Oncology, Schulich School of Medicine & Dentistry, London, ON, Results: Cyproheptadine resulted in improved blood pressure and allowed for a dose reduction in Canada N6A 5W9 other antihypertensives, but elevated liver transaminases and suspected hepatotoxicity several weeks 5 Department of Paediatrics, Division of later resulted in the discontinuation of this treatment. Neurology, Schulich School of Medicine & Dentistry, London, ON, Canada N6A Conclusions: Despite the safety concerns associated with using cyproheptadine to treat paediatric 5W9 central hypertension, this treatment holds promise for persistent refractory hypertension as a last-line *Email: [email protected] agent when all other treatment options are exhausted.
    [Show full text]
  • Treatment of Anorexia and Weight Loss with Megestrol Acetate in Patients with Cystic Fibrosis
    Pediatric Pulmonology 28:380–382 (1999) Treatment of Anorexia and Weight Loss With Megestrol Acetate in Patients With Cystic Fibrosis Samya Z. Nasr, MD,1* Martin E. Hurwitz, MD,1 Randall W. Brown, MD,1 Mahmoud Elghoroury, MD,3 and David Rosen, MD2 Summary: Four patients with severe cystic fibrosis lung disease, anorexia and weight loss, received Megestrol Acetate (MA), as an appetite stimulant. The initial dose was 400–800 mg daily and was continued for 6–15 months. Appetite was improved, with significant weight gain in all patients and an increase in their weight for age percentile from <5% at the start of the study to approximately the 25th percentile after 6 months of use and improvement in quality of life. One patient discontinued MA after 6 months, and subsequently appetite and weight were depressed. Pediatr Pulmonol. 1999; 28:380–382. © 1999 Wiley-Liss, Inc. Key words: cystic fibrosis; megestrol acetate; anorexia. INTRODUCTION ated in these patients to stimulate their appetite. This appears to be an innovative way of treating these termi- Weight loss is a common problem in patients with nally ill patients to improve their nutritional status and advanced cystic fibrosis (CF). 24.4% of patients with CF decrease their pulmonary symptoms. fell below the fifth percentile of weight for age in 1996.1 Inadequate weight gain in CF is thought to be due to energy imbalance related to the increased caloric de- CASE REPORTS mands of chronic respiratory disease, and possibly an elevated metabolic rate compounded by malabsorption Four children and adolescents with CF (3 females and and anorexia.2 With progression of the pulmonary dis- 1 male) ages 10–18.5 years, received MA in an effort to ease and anorexia, some patients may fail to gain weight stimulate their appetite and improve weight gain.
    [Show full text]
  • Pain Assessment and Treatment in Children with Significant Impairment of the Central Nervous System Julie Hauer, Amy J
    CLINICAL REPORT Guidance for the Clinician in Rendering Pediatric Care Pain Assessment and Treatment in Julie Hauer, MD, FAAP, a, b Amy J. Houtrow, MD, PhD, MPH, FAAP, c SECTION ON HOSPICE ChildrenAND PALLIATIVE MEDICINE, COUNCIL With ON CHILDREN Significant WITH DISABILITIES Impairment of the Central Nervous System Pain is a frequent and significant problem for children with impairment abstract of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment. Despite the significance of the problem, this population remains vulnerable to underrecognition and undertreatment of pain. Barriers to treatment may include uncertainty in identifying pain along with limited experience and fear with the use of aComplex Care Service, Division of General Pediatrics, Boston medications for pain treatment. Behavioral pain-assessment tools are Children’s Hospital, Assistant Professor, Harvard Medical School, Boston Massachusetts; bSeven Hills Pediatric Center, Groton, reviewed in this clinical report, along with other strategies for monitoring Massachusetts; and cDepartment of Physical Medicine and Rehabilitation, University of Pittsburgh, Pediatric Rehabilitation pain after an intervention. Sources of pain in this population include Medicine, Rehabilitation Institute, Children’s Hospital of Pittsburgh of acute-onset pain attributable to tissue injury or inflammation resulting UPMC, Pittsburgh, Pennsylvania in nociceptive pain, with pain then expected to resolve after treatment Dr Hauer conceptualized and drafted the initial manuscript, reviewed and responded to questions and comments from all reviewers, and directed at the source. Other sources can result in chronic intermittent pain contributed to writing the final manuscript; Dr Houtrow contributed that, for many, occurs on a weekly to daily basis, commonly attributed to to the initial drafting and editing at all stages, including the final manuscript; and all authors approved the final manuscript as gastroesophageal reflux, spasticity, and hip subluxation.
    [Show full text]